Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of September 2019. The report details the results of a Special General Meeting of Shareholders held on September 26, 2019, at the company's principal executive offices in Rehovot, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses solely on the approval of corporate governance proposals.
Guidance, Outlook, and Management Commentary
There is no financial guidance, outlook, or management commentary regarding business performance in this filing. The meeting approved two specific proposals:
- Approval of an updated compensation policy for directors and other office holders in accordance with the Israeli Companies Law.
- Approval of renewed Directors' and Officers' (D&O) Liability insurance coverage, effective October 1, 2019.
No risks, contingencies, or unusual items were disclosed in this specific report.
Key Facts for Investor Verification
- Shareholders approved a new director compensation policy.
- D&O insurance coverage was renewed effective October 1, 2019.
- This filing contains no financial data; investors should refer to the company's Form 20-F or quarterly reports for financial performance.